B. Jaber

Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy

E. Mercuri, R. Sergott, S. Nave, 2020, Annals of clinical and translational neurology.

A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier

T. Bergauer, O. Khwaja, K. Heinig, 2018, British journal of clinical pharmacology.

Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

J. Kremer, M. Greenwald, N. Gaylis, 2014, BMC Musculoskeletal Disorders.

Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

G. Comi, C. Palermo, M. Pane, 2022, The Lancet Neurology.

Moclobemide safety: monitoring a newly developed product in the 1990s.

B. Jaber, S. Hilton, S. Hilton, 1995, Journal of clinical psychopharmacology.

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam

T. Marbury, K. Heinig, A. Günther, 2022, British journal of clinical pharmacology.

Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study

R. Finkel, M. Pane, A. Mayhew, 2023, Neurology and Therapy.